Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

21 April 2022: Articles

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation

Unusual clinical course, Unusual or unexpected effect of treatment

Michael Cass A* , Andrew B. McDonald B , Osnat Ben-Shahar D , Yosef Landesman C , Trinayan Kashyap C

DOI: 10.12659/AJCR.935353

Am J Case Rep 2022; 23:e935353

Figure 1. Timeline of treatments given to the patient between diagnosis and until commencing treatment with selinexor. ASCT – autologous stem cell transplantation; CR – complete response; CTD – cyclophosphamide, thalidomide, dexamethasone; DCEP – dexamethasone, cyclophosphamide, etoposide, cisplatin; HDM – high-dose melphalan; ICd – ixazomib, cyclophosphamide, prednisone; IRd – ixazomib, lenalidomide, dexamethasone; PAD – bortezomib, doxorubicin, dexamethasone; Pom/Dex – pomalidomide, dexamethasone; PD – progressive disease; PR – partial response; SD – stable disease; XVd – selinexor, bortezomib, dexamethasone; VAD – vincristine, doxorubicin, dexamethasone; VGPR – very good partial response.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923